Gilead (GILD) Weekly Harvoni Scripts Data Shows Gains

Gilead Sciences (NASDAQ: GILD) Harvoni TRx for the week ending Feb. 6 was 8455, up 10% week-over-week, according to RBC Capital, citing Symphony data. Harvoni NRx was 4267, up 1%. Harvoni+Sovaldi TRx was 10781, up 10%, and NRx was 5296, up 1%.

AbbVie (NYSE: ABBV) Viekira Pak TRx was 255, up 19% week-over-week, and NRx was 210, up 6%.

"IMS just announced a data delay for today, and thus we are reporting Symphony scripts first," said RBC analyst Michael J. Yee. "WK Sovaldi and Harvoni scripts have been similar to IMS data within ~10% difference."

"IMS Viekira Pak scripts have been 40-50% lower than Symphony scripts, perhaps due to a restriction on IMS Viekira Pak scripts. This early in the launch, capture rate may also vary and be uncertain," he added.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $100.80 yesterday.

You May Also Be Interested In

• EU approves Gilead's Trodelvy combo with Keytruda for front-line TNBC
• Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
• Stereotaxis (STXS) PT Lowered to $3 at Citizens on Top-Line Miss, Guidance Cut